@article{4073,
  keywords = {Humans, Proteomics, Adult, Kidney, Prospective Studies, Precision Medicine, Acute Kidney Injury, Renal Insufficiency, Chronic},
  author = {Ian de Boer and Charles Alpers and Evren Azeloglu and Ulysses Balis and Jonathan Barasch and Laura Barisoni and Kristina Blank and Andrew Bomback and Keith Brown and Pierre Dagher and Ashveena Dighe and Michael Eadon and Tarek El-Achkar and Joseph Gaut and Nir Hacohen and Yongqun He and Jeffrey Hodgin and Sanjay Jain and John Kellum and Krzysztof Kiryluk and Richard Knight and Zoltan Laszik and Chrysta Lienczewski and Laura Mariani and Robyn McClelland and Steven Menez and Dennis Moledina and Sean Mooney and John O{\textquoteright}Toole and Paul Palevsky and Chirag Parikh and Emilio Poggio and Sylvia Rosas and Matthew Rosengart and Minnie Sarwal and Jennifer Schaub and John Sedor and Kumar Sharma and Becky Steck and Robert Toto and Olga Troyanskaya and Katherine Tuttle and Miguel Vazquez and Sushrut Waikar and Kayleen Williams and Francis Wilson and Kun Zhang and Ravi Iyengar and Matthias Kretzler and Jonathan Himmelfarb and Kidney Precision Medicine Project},
  title = {Rationale and design of the Kidney Precision Medicine Project.},
  abstract = { <p>Chronic kidney disease (CKD) and acute kidney injury (AKI) are common, heterogeneous, and morbid diseases. Mechanistic characterization of CKD and AKI in patients may facilitate a precision-medicine approach to prevention, diagnosis, and treatment. The Kidney Precision Medicine Project aims to ethically and safely obtain kidney biopsies from participants with CKD or AKI, create a reference kidney atlas, and characterize disease subgroups to stratify patients based on molecular features of disease, clinical characteristics, and associated outcomes. An additional aim is to identify critical cells, pathways, and targets for novel therapies and preventive strategies. This project is a multicenter prospective cohort study of adults with CKD or AKI who undergo a protocol kidney biopsy for research purposes. This investigation focuses on kidney diseases that are most prevalent and therefore substantially burden the public health, including CKD attributed to diabetes or hypertension and AKI attributed to ischemic and toxic injuries. Reference kidney tissues (for example, living-donor kidney biopsies) will also be evaluated. Traditional and digital pathology will be combined with transcriptomic, proteomic, and metabolomic analysis of the kidney tissue as well as deep clinical phenotyping for supervised and unsupervised subgroup analysis and systems biology analysis. Participants will be followed prospectively for 10 years to ascertain clinical outcomes. Cell types, locations, and functions will be characterized in health and disease in an open, searchable, online kidney tissue atlas. All data from the Kidney Precision Medicine Project will be made readily available for broad use by scientists, clinicians, and patients.</p> },
  year = {2021},
  journal = {Kidney Int},
  volume = {99},
  pages = {498-510},
  month = {2021 Mar},
  issn = {1523-1755},
  doi = {10.1016/j.kint.2020.08.039},
  language = {eng},
}